Bharat Parenterals: Un-Audited Standalone and Consolidated Financial Results For the Quarter and Half Year Ended On September…

What happened

Bharat Parenterals (BPLPHARMA) filed a disclosure with the exchanges on 29 October 2026 at 05:05 PM titled "Un-Audited Standalone and Consolidated Financial Results For the Quarter and Half Year Ended On September 30, 2026".

Company snapshot

Bharat Parenterals is a small-cap company, with a market value of about ₹1,318 crore.

The stock last traded at ₹1,912.6, against a 52-week range of ₹1,201.1–₹2,277.6 (16.0% below the high).

Before this filing the shares had moved +0.8% over the month. Average daily turnover over the last 20 sessions was about ₹2.01 crore.

Promoters held 67.20% at the end of Q1 FY27, up 0.03% points from the previous quarter. Foreign institutions owned 0.11% and domestic institutions 1.37%.

What history shows

BCEIE has no earlier results filing from this company on record since May 2026.

Market-wide, 9,836 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

• Management commentary, margins and order book or guidance in the investor presentation.

In the news

Recent coverage elsewhere (links open the original publisher):

• Bharat Parenterals schedules EGM on Oct 23 to approve ₹139 crore preferential issue — scanx.trade, 23 Oct 2026
• Bharat Parenterals Ltd. Estimates – BSE:BPLPHARMA — TradingView, 27 Oct 2026
• Bharat Parenterals shines as its arm commences commercial supply to United States — Investment Guru, 22 Oct 2026
• Bharat Parenterals Subsidiary Innoxel Starts U.S. Commercial Sales With October 20 Launch — Sahi, 21 Oct 2026
• Bharat Parenterals revises EGM voting results to correct categorization — scanx.trade, 23 Oct 2026

Source

• Exchange filing (PDF)